Victory Capital Management Inc. Purchases Shares of 10,183 OmniAb, Inc. (NASDAQ:OABI)

Victory Capital Management Inc. purchased a new stake in OmniAb, Inc. (NASDAQ:OABI) in the second quarter, HoldingsChannel reports. The fund purchased 10,183 shares of the company’s stock, valued at approximately $51,000.

Other hedge funds have also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC bought a new stake in OmniAb in the 2nd quarter valued at $38,000. Stephens Inc. AR bought a new position in shares of OmniAb during the 1st quarter worth about $32,000. Bailard Inc. bought a new position in shares of OmniAb during the 2nd quarter worth about $50,000. Stifel Financial Corp bought a new position in shares of OmniAb during the 1st quarter worth about $37,000. Finally, Ameritas Advisory Services LLC bought a new position in shares of OmniAb during the 2nd quarter worth about $52,000. 58.73% of the stock is owned by institutional investors.

OmniAb Stock Down 3.0 %

Shares of OmniAb stock opened at $4.56 on Tuesday. The stock has a market capitalization of $529.73 million, a P/E ratio of -19.83 and a beta of -0.43. The company has a 50-day simple moving average of $5.08 and a 200 day simple moving average of $4.80. OmniAb, Inc. has a 12-month low of $1.91 and a 12-month high of $5.97.

OmniAb (NASDAQ:OABI) last announced its earnings results on Thursday, August 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.04). The company had revenue of $6.95 million for the quarter, compared to analyst estimates of $13.05 million. On average, equities analysts anticipate that OmniAb, Inc. will post -0.45 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of OmniAb in a report on Friday, August 11th. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, OmniAb presently has a consensus rating of “Buy” and a consensus price target of $10.00.

Insider Buying and Selling

In other news, CEO Matthew W. Foehr bought 45,000 shares of the company’s stock in a transaction that occurred on Monday, August 14th. The stock was acquired at an average price of $5.48 per share, for a total transaction of $246,600.00. Following the transaction, the chief executive officer now directly owns 2,332,919 shares of the company’s stock, valued at approximately $12,784,396.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 7.00% of the stock is currently owned by corporate insiders.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the provision of therapeutic antibody discovery technologies in the United States. The company's discovery platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates.